GE Additive, global leader in metal additive manufacturing (AM) and design has entered into a key strategic partnership with orthopedic device manufacturer Orchid Orthopedic Solutions.
GE Additive and Orchid Orthopedic Form Key Partnership
The partnership between the two companies plays to both firm’s strengths. GE Additive brings to Orchid the ability to produce and market scalable metal 3D printing technology for large joint orthopedic implants. The two companies intend to jointly market their combined capabilities in order to build customer awareness of the features and benefits of electron beam melting (EBM) medical device solutions. GE Additive brands are Concept Laser, Arcam EBM, and AP&C.
“I am honored that Orchid has put their confidence and trust in GE’s additive expertise, at such an important juncture in their metal AM journey. I look forward to our teams building a long-term relationship over the coming years,” said GE Additive President and Chief Executive Officer Riccardo Procacci. “I have personal experience overseeing the deployment of a large fleet of industrialized EBM machines for precise scalable AM production at GE Aviation’s Avio Aero business, so I look forward to getting to know the Orchid team and sharing some of my insights. I also continue to be amazed at how our existing medical customers and orthopedic community are using metal additives to innovate and drive better and often personalized outcomes for patients.”
Cincinnati-based GE Additive, a part of General Electric, is an international pioneer in metal additive production, design, and business solutions. The company’s advanced machines, high quality powders, and additive manufacturing experts support customers and create innovative products and solutions.
Orchid Orthopedic Solutions, headquartered in Michigan, provides medical device solutions and manufacturing to customers around the world. Orchid’s brand is that it delivers one of the broadest arrays of implants, single use instruments, and innovative technologies for joint reconstruction, trauma, spine, extremities and dental in the industry.
“We are thrilled to collaborate with GE Additive to bring additive manufacturing capabilities to our customers,” said Orchid Chief Executive Officer Nate Folkert. “GE Additive has an excellent reputation and is a market leader in the additive space. Together with our extensive knowledge of large joint orthopedic manufacturing, we will be able to serve customers like never before. They will have the assurance that we are taking an extra level of care by partnering with GE Additive. I look forward to seeing Orchid drive continued additive manufacturing innovation as a result of this Agreement.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.